Dr. Mahsa Mohebtash, MD

Dr. Mohebtash practices at MedStar Franklin Square Medical Center in Rosedale, Maryland, part of MedStar Health.

Dr. Mohebtash's NPI, 1609074038, was assigned on July 6, 2007. Dr. Mohebtash holds Maryland license D0064648.

Dr. Mohebtash's primary practice is MedStar Franklin Square Medical Center, at 9000 Franklin Square Drive, Rosedale, MD 21237 in Baltimore County. The practice phone is (443) 777-7850.

Dr. Mohebtash's primary practice is MedStar Franklin Square Medical Center in Rosedale, Maryland, part of MedStar Health. Dr. Mohebtash is also affiliated with MedStar Good Samaritan Hospital. The medical group on file is MedStar Medical Group. Dmand AI also links Dr. Mohebtash to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mohebtash practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mohebtash's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Mohebtash is licensed in Maryland.

CMS data shows 1,936 Medicare services from Dr. Mohebtash across 7 procedure codes in 2024, for 446 Medicare patients. Medicare paid $121,863 for them.

CMS counts 446 Medicare patients who saw Dr. Mohebtash in 2024. The largest group is 65 to 74, with 200 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mohebtash's median patient age at 69, with 81% women.

In 2024, Dr. Mohebtash wrote 377 Medicare Part D claims for 130 patients. 83% of them were for generic drugs. CMS names the drug for 203 of them, across 8 drugs with 11 or more claims each, at $286,861 in total drug cost. In 2023, CMS named 203 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Mohebtash for performance year 2024, reported as part of a group. Dr. Mohebtash accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mohebtash as offering telehealth.

Dmand AI links 17 papers to Dr. Mohebtash, published from 2011 to 2025. 2017 was the busiest year, with 4. The most frequent topics are Breast Neoplasms, Cancer Vaccines and Antineoplastic Agents. Dr. Mohebtash has published most often in J Community Hosp Intern Med Perspect. Dr. Mohebtash's most frequent co-authors are Philip Martin Arlen, MD, Asma Ali Dilawari, MD and Ravi Amrit Madan, MD.

Dmand AI links Dr. Mohebtash to 7 clinical trials, 4 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Breast Neoplasms, Male. Georgetown University sponsors the most, 2.

CMS Open Payments shows 85 general payments to Dr. Mohebtash from 26 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 51% of the total. Amgen Inc. paid the most, $4,966.